Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)
China
· Delayed Price · Currency is CNY 25.26
+0.06 (0.24%)
May 12, 2025, 2:45 PM CST
Cabio Biotech (Wuhan) Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 144.9 | 124.21 | 91.37 | 64.37 | 128.58 | 130.59 | Upgrade
|
| Depreciation & Amortization | 55.37 | 55.37 | 48.35 | 27 | 23.96 | 26.01 | Upgrade
|
| Other Amortization | 3.13 | 3.13 | 1.73 | 0.57 | 0.08 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 0 | 0 | -0.05 | -0 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 13.34 | 13.34 | 9.66 | 35.97 | -2.1 | 1.8 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.94 | -1.94 | -2.46 | 1.04 | -8.73 | -20.45 | Upgrade
|
| Provision & Write-off of Bad Debts | -4.61 | -4.61 | 7.03 | 15.67 | 6.12 | 0.03 | Upgrade
|
| Other Operating Activities | -35.76 | -4.58 | -6.15 | -7.06 | -0.85 | 11.5 | Upgrade
|
| Change in Accounts Receivable | -0.47 | -0.47 | -45.73 | -61.48 | -47.72 | -9.68 | Upgrade
|
| Change in Inventory | -39.94 | -39.94 | -39.59 | -9.22 | -4.87 | 2.58 | Upgrade
|
| Change in Accounts Payable | 29.06 | 29.06 | 7.51 | 100.12 | 8.99 | 3.66 | Upgrade
|
| Change in Other Net Operating Assets | -2.09 | -2.09 | -2.92 | 14.66 | - | - | Upgrade
|
| Operating Cash Flow | 162.55 | 173.04 | 68.89 | 176.4 | 103.29 | 145.88 | Upgrade
|
| Operating Cash Flow Growth | 38.27% | 151.19% | -60.95% | 70.78% | -29.20% | 10.56% | Upgrade
|
| Capital Expenditures | -197 | -211.6 | -297.68 | -249.47 | -173.43 | -33.1 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.05 | 0.1 | 0.27 | 0.16 | 0.19 | 0.17 | Upgrade
|
| Investment in Securities | 9.34 | -15.66 | 2.62 | -97.91 | -88.86 | -66.77 | Upgrade
|
| Other Investing Activities | 44.91 | 1.14 | 7.49 | 8.69 | 11.72 | 19.22 | Upgrade
|
| Investing Cash Flow | -142.7 | -226.03 | -287.3 | -338.53 | -250.37 | -80.48 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 30 | 30 | - | Upgrade
|
| Long-Term Debt Issued | - | 18.61 | 11 | - | - | - | Upgrade
|
| Total Debt Issued | 52.26 | 18.61 | 11 | 30 | 30 | - | Upgrade
|
| Short-Term Debt Repaid | - | -11 | -30 | - | -30 | - | Upgrade
|
| Long-Term Debt Repaid | - | -11.96 | -1.35 | -0.99 | -0.97 | - | Upgrade
|
| Total Debt Repaid | -22.96 | -22.96 | -31.35 | -0.99 | -30.97 | - | Upgrade
|
| Net Debt Issued (Repaid) | 29.31 | -4.34 | -20.35 | 29.01 | -0.97 | - | Upgrade
|
| Issuance of Common Stock | - | - | 6.39 | - | - | - | Upgrade
|
| Common Dividends Paid | -34.07 | -34.02 | -36.58 | -39.85 | -39.87 | -60 | Upgrade
|
| Other Financing Activities | -4.35 | - | 16.53 | - | 1.47 | -3.95 | Upgrade
|
| Financing Cash Flow | -9.12 | -38.36 | -34.02 | -10.83 | -39.37 | -63.95 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1.56 | 0.9 | 1.46 | 7.02 | -1.81 | -0.94 | Upgrade
|
| Net Cash Flow | 12.29 | -90.44 | -250.96 | -165.94 | -188.26 | 0.52 | Upgrade
|
| Free Cash Flow | -34.45 | -38.55 | -228.79 | -73.07 | -70.14 | 112.78 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | - | 3.78% | Upgrade
|
| Free Cash Flow Margin | -5.79% | -6.94% | -51.55% | -16.86% | -19.98% | 34.87% | Upgrade
|
| Free Cash Flow Per Share | -0.21 | -0.23 | -1.35 | -0.43 | -0.42 | 0.67 | Upgrade
|
| Cash Income Tax Paid | 33.97 | 29.66 | 49.04 | 26.62 | 39.54 | 48.93 | Upgrade
|
| Levered Free Cash Flow | -120.31 | -128.6 | -342.35 | -139.91 | -135.83 | 64.58 | Upgrade
|
| Unlevered Free Cash Flow | -120.03 | -128.35 | -341.98 | -139.68 | -135.61 | 64.58 | Upgrade
|
| Change in Net Working Capital | 59.99 | 39.6 | 137.57 | -28.59 | 49.78 | -3.06 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.